SAFETY PROFILE
Adverse reaction profile with AUGTYRO in the TRIDENT-1 study1
The ROS1+ NSCLC safety population included 264 patients from Phase 2 study cohorts who received the recommended dose of AUGTYRO1
8% of patients permanently discontinued AUGTYRO1
Serious adverse reactions occurred in 33% of patients who received AUGTYRO. Serious adverse reactions reported in ≥2% of patients included pneumonia, dyspnea, pleural effusion, and hypoxia. Fatal adverse reactions were reported in 4.2% of patients who received AUGTYRO, including death, pneumonia, pneumonia aspiration, cardiac arrest, sudden cardiac death, cardiac failure, sudden death, hypoxia, dyspnea, respiratory failure, tremor, and disseminated intravascular coagulation.1
Adverse Reaction1* (≥10%) in patients taking AUGTYRO |
AUGTYRO (N=264) |
All Grades % |
Grade 3 or 4% |
Nervous System Disorders |
|
|
Dizzinessa |
63 |
1.9 |
Dysgeusiab
| 48 |
0 |
Peripheral neuropathyc |
47 |
1.9 |
Ataxiad |
28 |
0.4 |
Cognitive disorderse |
23 |
0.8 |
Headachef |
19 |
0 |
Gastrointestinal Disorders |
|
|
Constipation |
36 |
0 |
Nausea |
19 |
0.4 |
Diarrhea |
13 |
0.4 |
Vomiting |
10 |
0.8 |
Respiratory, Thoracic, and Mediastinal Disorders |
|
|
Dyspneag |
30 |
7 |
Coughh |
14 |
0 |
General Disorders |
|
|
Fatiguei |
24 |
1.1 |
Edemaj |
12 |
0.8 |
Musculoskeletal and Connective Tissue Disorders |
|
|
Muscular weakness |
21 |
1.5 |
Myalgiak |
12 |
0.4 |
Metabolism and Nutritional |
|
|
Increased weight |
14 |
1.9 |
Eye Disorders |
|
|
Vision disordersl |
11 |
0 |